Sponsored by Lonza 3 Sep 2024 The crucial role of GS-CHO innovation in biopharmaceutical progress Learn how GS-CHO systems are advancing to improve yields and quality in biomanufacturing, meeting the rising need for effective therapeutic proteins. September 3, 2024 - 8 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 27 Aug 2024 Could microbiome drugs be the key to unlocking checkpoint inhibitors’ potential? As Microbiotica announces phase 1 approval for two microbiome drugs we delve into their potential in oncology and beyond. August 27, 2024 - 11 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 14 Aug 2024 CAR-T drugs and parkinsonism: a cause for concern? CAR-T therapies come with boxed warnings of serious neurotoxic side effects. Now, growing concerns over parkinsonism have led to a clinical trial halt. August 14, 2024 - 3 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 13 Aug 2024 Biologics vs. drugs: What does Ipsen’s lost case against the FDA mean for the industry? Ipsen has lost a court case against U.S. regulators to have its blockbuster cancer medication Somatuline Depot regarded as a biologic instead of a drug. August 13, 2024 - 4 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
More News! 23 Jul 2024 First AKT-targeting drug capivasertib to hit the market, could it open the door for more? As AstraZeneca and Astex’s capivasertib gains market presence in breast cancer, could it be the time for AKT inhibitors? Let’s find out! July 23, 2024 - 7 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 16 Jul 2024 German biotech raises $150M on its way to tackle cancer therapy resistance On its way to tackle cancer therapy resistance with its monoclonal antibody visugromab, CataLym completes a $150 million series D round. July 16, 2024 - 9 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Podcast 5 Jul 2024The radiotherapeutics boom The field of radiotherapeutics is a hot topic currently. Listen to our conversation with three experts in the field. July 5, 2024 Share WhatsApp Twitter Linkedin Email Listen Now Apple Music Spotify More
Inside Labiotech 3 Jul 2024 2024 survey: What can Labiotech readers tell us about the biotech industry? Explore key insights into the latest biotech industry trends based on our 2024 reader survey findings. Discover more now! July 3, 2024 - 4 minutesmins - By Joachim Eeckhout Share WhatsApp Twitter Linkedin Email
In Depth 28 Jun 2024 Going nuclear: radiopharmaceuticals funding sees surge in 2024 Emerging as a new class of drugs, radiopharmaceuticals are all the rage in cancer treatment research as biotechs nab major funding deals. June 28, 2024 - 6 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 27 Jun 2024 The 2024 drug approval list: Eight new treatments you should know about In this article, we take a look at eight much-anticipated drugs that have been approved by regulators so far this year. June 27, 2024 - 9 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Podcast 21 Jun 2024How ADCs can deliver death cap mushroom toxins to treat cancer Listen to our conversation with Heidelberg Pharma about its lead amanitin-based ADC product candidate, HDP-101. June 21, 2024 Share WhatsApp Twitter Linkedin Email Listen Now Apple Music Spotify More
Best in Biotech 13 Jun 2024 Eight companies tackling cancer with allogeneic cell therapy in 2024 Unlike autologous cell therapy, where the patient’s own cells are used, allogeneic cell therapy companies leverage donor cells, which can come from various sources such as bone marrow or umbilical cord blood. In allogeneic cell therapy, healthy donor cells are harvested, processed, and then infused into the patient. These donor cells can differentiate into various […] June 13, 2024 - 9 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email